Collecting tumor samples and clinical data from people with pelvic gynecological cancer
Collects tumor samples and clinical information from adults with pelvic gynecological cancers.
Plain-language title generated from the registry record
Registry title: Cohort of Patients With Pelvic Gynecological Cancer: Constitution of a Collection of Biological Samples With Radioclinical Characterization
Key facts
- Where
- Créteil and Paris, FranceSee the 2 sites
Where in France
- Chi CreteilCréteil, FranceTaking people
- CHU TenonParis, FranceTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Centre Hospitalier Intercommunal Creteil
- Trial code
- NCT03622983
- Record updated
- 21 December 2022
- Original description
The management of pelvic gynecological cancers (PGC) is based on the determination of extension to guide treatments. The biology of the CGP is constantly evolving and personalized medicine adapted to this biology is currently in full development. For example, sequencing ovarian tumors can select patients who can benefit from anti-PARP therapy. There is therefore a need for patients to have biological samples of their tumor. Various studies on ovarian, endometrial and cervical cancer have sought to identify the factors predictive of recurrence of these cancers. The results obtained are very promising. This study will permit to collect biological samples and detailed clinical data that would allow to test hypotheses and develop a personalized medicine based on clinical and biological characteristics of patients.Read full original descriptionShow less
Cohort of Patients With Pelvic Gynecological Cancer: Constitution of a Collection of Biological Samples With Radioclinical Characterization
The management of pelvic gynecological cancers (PGC) is based on the determination of extension to guide treatments. The biology of the CGP is constantly evolving and personalized medicine adapted to this biology is currently in full development. For example, sequencing ovarian tumors can select patients who can benefit from anti-PARP therapy. There is therefore a need for patients to have biological samples of their tumor. Various studies on ovarian, endometrial and cervical cancer have sought to identify the factors predictive of recurrence of these cancers. The results obtained are very promising. This study will permit to collect biological samples and detailed clinical data that would allow to test hypotheses and develop a personalized medicine based on clinical and biological characteristics of patients.
Inclusion: Diagnosis of pelvic gynecological cancer posed on initial histological analysis or during recurrence; Or diagnosis of endometriosis on histology or imaging; Age ≥ 18 years; Affiliation to the general social security scheme; Consent signed.
Exclusion: Refusal of the patient; Non-affiliation to the general social security scheme.